Abstract:Colorectal cancer (CRC) is the third most prevalent one in the world among the most common malignant tumors. Numerous studies have shown that butyrate has demonstrated promise as an antitumor agent in a variety of human cancer types. However, butyrate remains understudied in CRC tumorigenesis and progression. In this study, we explored therapeutic strategies to treat CRC by examining the role of butyrate metabolism. First, from the Molecular Signature Database (MSigDB), we identified 348 butyrate metabolism-related genes (BMRGs). Next, we downloaded 473 CRC and 41 standard colorectal tissue samples from The Cancer Genome Atlas (TCGA) database and the transcriptome data of GSE39582 dataset from Gene Expression Omnibus (GEO) database. Then we evaluated the expression patterns of butyrate metabolism-related genes with difference analysis in CRC. Through univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analysis, a prognostic model was constructed based on differentially expressed BMRGs. In addition, we discovered an independent prognostic marker for CRC patients. According to the expression levels and coefficients of identified BMRGs, the risk scores of all CRC samples were calculated. Utilizing differentially expressed genes in the high- and low-risk groups, we also constructed a Protein-Protein Interaction (PPI) network to visualize the interactions between proteins. Through the results of PPI network, we screened out differentially expressed target butyrate metabolism-related genes from ten hub genes. Finally, we performed clinical correlation analysis, immune cell infiltration analysis, and mutation analysis for these target genes. One hundred and seventy three differentially expressed butyrate metabolism-related genes were screened out in all the CRC samples. The prognostic model was established with univariate Cox regression and LASSO regression analysis. CRC patients' overall survival was significantly lower in the high-risk group than in the low-risk group for both training and validation set. Among the ten hub genes identified from the PPI network, four target butyrate metabolism-related genes were identified containing FN1, SERPINE1, THBS2, and COMP, which might provide novel markers or targets for treating CRC patients. Eighteen butyrate metabolism-related genes were used to develop a risk prognostic model that could be helpful for doctors to predict CRC patients' survival rate. Using this model, it is beneficial to forecast the response of CRC patients to immunotherapy and chemotherapy, thus making it easier to custom tailor cancer chemotherapy and immunotherapy to the individual patient.

Supplementation of Probiotic Butyricicoccus pullicaecorum Mediates Anticancer Effect on Bladder Urothelial Cells by Regulating Butyrate-Responsive Molecular Signatures

Specific vaginal and gut microbiome and the anti-tumor effect of butyrate in cervical cancer women

Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota

Gut Microbial Metabolite Butyrate Improves Anticancer Therapy by Regulating Intracellular Calcium Homeostasis

Sodium Butyrate Inhibits Migration and Induces AMPK-mTOR Pathway-Dependent Autophagy and ROS-mediated Apoptosis Via the Mir-139-5p/bmi-1 Axis in Human Bladder Cancer Cells.

Gut microbiota Parabacteroides distasonis enchances the efficacy of immunotherapy for bladder cancer by activating anti-tumor immune responses

Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer

Gut Microbial Composition Changes in Bladder Cancer Patients: A Case-Control Study in Harbin, China.

Effects of Intestinal Microbial⁻Elaborated Butyrate on Oncogenic Signaling Pathways

Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China

Probiotics Clostridium Butyricum and Bacillus Subtilis Ameliorate Intestinal Tumorigenesis

Modulation of Gut Microbiota by Probiotics to Improve the Efficacy of Immunotherapy in Hepatocellular Carcinoma

Probiotics enhances anti-tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer

In situ delivery of biobutyrate by probiotic Escherichia coli for cancer therapy

Microbiome and bladder cancer: the role of probiotics in treatment

Butyrate's (a short-chain fatty acid) microbial synthesis, absorption, and preventive roles against colorectal and lung cancer

Bladder Cancer-Associated Microbiota: Recent Advances and Future Perspectives

Characterization of Butyrate-Metabolism in Colorectal Cancer to Guide Clinical Treatment

Effects of Probiotics on Chemotherapy in Patients with Lung Cancer

Clostridium butyricum and its metabolite butyrate promote ferroptosis susceptibility in pancreatic ductal adenocarcinoma

Abstract 2809: Bifidobacterium species BB_003 identified through metatranscriptomic analysis with experimentally validated antitumor actions